Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults

Exclusion Criteria

• •Unable or unwilling to give informed consent in either study group
• •Current psychiatric disorder not currently under control or being adequately treated
• •Current consumption of more than 14 alcoholic drinks per week
• •Self-reported inability to walk across a small room
• •Residence in a nursing home
• •Previous MOCA score below 21
• •Difficulty in communication with study personnel due to speech or hearing problems
• •Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
• •Elective surgery, planned prior to signing consent
• •Severe osteoarthritis
• •Rheumatoid arthritis
• •Severe B/L hip, knee, or hand pain (\>7/10 on pain scale)
• •Cancer requiring treatment in the past three years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
• •Pulmonary disease including VQ mismatch/diffusion limitation, diminished inspired O2, hypoventilation, pulmonary fibrosis, or sarcoidosis
• •Current tobacco use (smoke/chew)
• •Currently prescribed corticosteroids
• •Patients taking nucleoside analogues (Zebularine, 5-azaC, Decitabine)
• •Patients on non-nucleoside analogues (Procaine, procainamide, hydralazine)
• •History of an inherited bleeding disorder or vitamin K deficiency
• •Cardiovascular disease (excluding HFpEF), clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator or uncontrolled angina.
• •Parkinson's disease or other serious neurological disorder
• •MMS score \< 18
• •Renal disease (any stage, inappropriate for age; Cr Cl \< 60)
• •Hypoalbuminemia, with serum albumin level \< 3.5 g/dL
• •History of IgA deficiency
• •History of hypersensitivity to frozen plasma (PF24) or to plasma-derived products including any plasma protein
• •Active hepatitis or history of liver transplant
• •Anemia or polycythemia: Male - Hgb level below 12 or above 17.5 g/dL and/or HCT of 41%-53%. Female: Hgb level below 10.0 or above 16.0 g/dL and/or HCT 36%-46%
• •Current use of anti-coagulants
• •History of DMI or DMII
• •Peripheral vascular disease
• •Brain aneurysm or intracranial hemorrhage within the past 6 months
• •History of Hepatitis B, Hepatitis C, or HIV infection
• •Other illness of such severity that life expectancy is considered to be less than 12 months
• •Patients with initial VO2max that falls below expected value or that does not meet a minimum VO2max of 20 mL \* kg \* min (in order to demonstrate a more clinically meaningful increase)
• •Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg)
• •CVA, hip fracture, B/L hip or knee replacement, or spinal surgery in the past 6 months
• •Serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG
• •Myocardial infarction, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis or pulmonary embolism in the past 6 months
• •Undergoing physical therapy or cardiopulmonary rehabilitation
• •Currently enrolled in another randomized trial involving lifestyle or pharmaceutical interventions
• •Currently on an anaerobic/aerobic exercise plan
• •Inability or unwillingness to return for all transfusions/FU visits